Supplementary Figure S1 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS^mut Disease Models

figure

posted on 2024-12-03, 08:22 authored by Jin Wu, Jianxin Wang, Thomas N. O’Connor, Stephanie L. Tzetzo, Katerina V. Gurova, Erik S. Knudsen, Agnieszka K. Witkiewicz

Supplementary Figure S1. A. Synergistic inhibition of various MEK inhibitors with CDK4/6 inhibitor palbociclib on HT1080 cell growth rate. B. BrdU incorporation in HT1080 cells treated with DMSO, CDK4/6i (palbociclib, 100 nmol/L), MEKi (pimasertib, 250 nmol/L), or in combination for 72 h. C. Heatmap illustrating relative BrdU incorporation in HT1080 cells after 72 h of CDK4/6i/MEKi (palbociclib/pimasertib) treatment (left) and synergy plot of CDK4/6i and MEKi treatment (right), determined using the BLISS method. D. BrdU incorporation in MIA PaCa-2 cells treated with DMSO, CDK4/6i (palbociclib, 100 nmol/L), MEKi (pimasertib, 250 nmol/L), or in combination, for 72 h. E. Heatmap illustrating relative BrdU incorporation in MIA PaCa-2 cells after 72 h of CDK4/6i/MEKi (palbociclib/pimasertib) treatment (left) and synergy plot of CDK4/6i and MEKi treatment (right), determined using the BLISS method. Data displayed as mean ± SD in triplicate. **p < 0.01, ****p < 0.0001 as determined by one-way ANOVA.

Funding

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

History

ARTICLE ABSTRACT

The combination of CDK4/6 and MEK inhibition as a therapeutic strategy has shown promise in various cancer models, particularly in those harboring RAS mutations. An initial high-throughput drug screen identified high synergy between the CDK4/6 inhibitor palbociclib and the MEK inhibitor trametinib when used in combination in soft tissue sarcomas. In RAS mutant models, combination treatment with palbociclib and trametinib induced significant G1 cell cycle arrest, resulting in a marked reduction in cell proliferation and growth. CRISPR-mediated RB1 depletion resulted in a decreased response to CDK4/6 and MEK inhibition, which was validated in both cell culture and xenograft models. Beyond its cell cycle inhibitory effects, pathway enrichment analysis revealed the robust activation of interferon pathways upon CDK4/6 and MEK inhibition. This induction of gene expression was associated with the upregulation of retroviral elements. The TANK-binding kinase 1 inhibitor GSK8612 selectively blocked the induction of interferon-related genes induced by palbociclib and trametinib treatment and highlighted the separable epigenetic responses elicited by combined CDK4/6 and MEK inhibition. Together, these findings provide key mechanistic insights into the therapeutic potential of CDK4/6 and MEK inhibition in soft tissue sarcomas.